Stelo’s expanded FDA label includes children aged two and older who are not using insulin, with caregiver supervision required for minors.

Dexcom announced the pediatric clearance on June 23. For parents, that creates a new possibility for obtaining glucose information without a prescription. It does not establish that every child needs a sensor—or that continuous tracking improves health in children with normal glucose.

The first decision is what question the family and clinician are trying to answer. Buying access to more measurements comes after that conversation.

Read the cleared population before the lifestyle pitch

The FDA’s Stelo decision summary excludes people using insulin, people with problematic hypoglycemia and those on dialysis. It requires a caregiver to supervise users under 18. Those conditions are central to the product’s permitted use, not minor qualifications to a general wellness promise.

A family dealing with an insulin-treated condition should not mistake this expansion for an interchangeable replacement for another diabetes-management system. A prescription-free purchase route also does not eliminate the need for professional interpretation when a reading raises a medical question.

More broadly, permission to market a device to an age group is different from evidence that routine use benefits everyone in that group. The technology’s ability to report glucose and the wisdom of adding it to a child’s daily life are separate issues.

Clearance and the retail experience are not yet aligned

October 12 verification update: Stelo’s current US retail page still states an age-18-and-older indication, despite the expanded FDA documentation and June announcement. That mismatch prevents a clean claim that the pediatric experience is generally available through the current storefront.

Before purchasing for a child, ask Dexcom which version and instructions implement the expanded indication, whether pediatric enrollment is supported, and how caregiver supervision works. Do not interpret an older retail description as overturning the regulator’s decision; equally, do not assume the clearance means every box and app flow has been updated.

This is an access story with an implementation question still open. That is a better description than either “now for all kids” or “adults only.”

What would make the extra data worthwhile?

An independent Associated Press report from July 2025 quoted an endocrinologist questioning the usefulness of glucose tracking for people with normal blood sugar. That is category context, not a pediatric Stelo trial. It reinforces the need to connect a measurement to a clinical purpose rather than treating more data as an outcome.

Ask what decisions would change, who will review the pattern, how long monitoring is needed and what would prompt stopping. Consider the child’s experience too: does the information support a specific care goal, or turn ordinary meals into a stream of scores that nobody can interpret responsibly?

Dexcom benefits from a wider potential market. Families may benefit when a suitable device fills a defined information gap. Families could also spend money and attention on monitoring that produces worry without changing care. The relevant evidence would compare pediatric outcomes and burdens, not simply report sensor uptake.

Watch for an updated pediatric user journey and transparent evidence identifying which children benefit, under what supervision and for which decisions. Until those pieces are clear, the practical step is a suitability discussion, not an automatic purchase.

Frequently Asked Questions

Can children using insulin use Stelo under this clearance?

No. Insulin users remain outside this indication. Their care team should identify the appropriate monitoring approach.

Does an over-the-counter label mean children can manage it alone?

No. The cleared instructions require caregiver supervision for users under 18.

Is pediatric Stelo generally available to buy now?

The checked retail wording still covers adults. Confirm the appropriate product version, instructions and enrollment route directly with Dexcom before a pediatric purchase.

Does clearance prove that healthy children should track glucose?

No. That broader preventive-benefit claim requires evidence for the relevant population and outcome; the announcement does not supply it.

Can a sensor reading replace professional medical advice?

No. Stelo’s retail instructions say not to take medical action based on its output without consulting a qualified healthcare professional.